English | Español

Johnson & Johnson
Press release submission | May 21, 2021

RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission | Dec 20, 2019

JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer

Press release submission | Jun 14, 2019

JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis

Trending
Patient Daily | Oct 22, 2025

Chronic Care Policy Alliance backs federal legislation to reform the 340B Drug Pricing Program
Patient Daily | Oct 23, 2025

Dallas Breathe Free ENT Specialist: Humidity 'tends to help' with sinus issues
Patient Daily | Oct 23, 2025

Capitol Breathe Free Otolaryngologist: ‘Allergy exacerbations are a common trigger for sinus infections'
Patient Daily | Oct 21, 2025

Gulf Coast Breathe Free Physician Assistant on sinus issues: ‘Certain things like dairy seem to increase mucus production’